文献速递肝病

住院肝硬化患者使用白蛋白对低钠血症纠正的影响

The Impact of Albumin Use on Resolution of Hyponatremia in Hospitalized Patients With Cirrhosis.
PubMed 文献 · Am J Gastroenterol · 2018-06-08

基于NACSELD队列的2435例住院肝硬化患者中1126例入院时存在低钠血症,其中777例接受静脉白蛋白(中位225 g,IQR 100-400 g),349例未接受。接受白蛋白者低钠血症纠正率更高(69% vs 61%,p=0.008),校正入院血钠和GFR后差异仍显著(85.41% vs 44.78%,p=0.0057,OR 1.50,95%CI 1.13-2.00)。低钠血症纠正与30天生存改善独立相关。

要点

  • 住院肝硬化合并低钠血症患者接受静脉白蛋白与更高的低钠血症纠正率独立相关。
  • 校正入院血钠和GFR后,白蛋白组低钠血症纠正率85.41% vs 未用组44.78%(p=0.0057,OR 1.50,95%CI 1.13-2.00)。
  • 低钠血症纠正、年龄、ACLF和入院GFR是30天生存的独立预测因素。

核心结论

  • 住院肝硬化合并低钠血症患者接受静脉白蛋白与更高的低钠血症纠正率独立相关,且该纠正与更好的30天生存相关。

研究设计与样本

  • 基于NACSELD队列的住院肝硬化患者研究,纳入2435例,其中1126例入院时存在低钠血症(Na<130 mmol/L),分为接受静脉白蛋白组(777例)和未接受组(349例)。

主要发现

  • 接受白蛋白组入院MELD评分、血清肌酐更高,入院血钠和平均动脉压更低。
  • 接受白蛋白组低钠血症纠正率69% vs 未接受组61%(p=0.008)。
  • 回归分析显示delta Na与入院肌酐、平均动脉压和白蛋白使用独立相关。
  • 协方差分析校正入院血钠和GFR后,白蛋白组低钠血症纠正率85.41% vs 未接受组44.78%(p=0.0057,OR 1.50,95%CI 1.13-2.00)。
  • 30天生存的独立预测因素为低钠血症纠正、年龄、ACLF和入院GFR。

关键数值与推荐

  • 低钠血症定义为入院血钠<130 mmol/L,纠正定义为血钠≥135 meq/L。
  • 白蛋白组接受白蛋白中位剂量225 g(IQR 100-400 g)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Hyponatremia is associated with poor outcomes in cirrhosis independent of MELD. While intravenous albumin has been used in small series, its role in hyponatremia is unclear. The aim of this study is to determine the effect of albumin therapy on hyponatremia. METHODS: Hospitalized cirrhotic patients included in the NACSELD (North American Consortium for End-Stage Liver Disease) cohort with hyponatremia (Na <130mmol/L) were divided into those receiving intravenous albumin or not. Determinants of hyponatremia resolution (Na ≥135 meq/L) and 30-day survival were analyzed using regression and ANCOVA models. RESULTS: Overall, 2435 patients, of whom 1126 had admission hyponatremia, were included. Of these, 777 received 225 (IQR 100,400) g of albumin, while 349 did not. Patients given albumin had a higher admission MELD score, and serum creatinine and lower admission Na and mean arterial pressure (MAP). However they experienced a higher maximum Na and hyponatremia resolution (69% vs 61%, p = 0.008) compared to those who did not. On regression, delta Na was independently associated with admission creatinine, MAP and albumin use. On ANCOVA with logistic regression, there was a significant difference in hyponatremia resolution between those who did or did not receive albumin, even after adjustment for admission Na and GFR (85.41% vs 44.78%, p = 0.0057, OR: 1.50 95% CI: 1.13-2.00). Independent predictors of 30-day survival were hyponatremia resolution, age, ACLF, and admission GFR. CONCLUSION: Hospitalized patients with cirrhosis and hyponatremia who received intravenous albumin had a higher rate of hyponatremia resolution independent of renal function and baseline sodium levels, which was in turn associated with a better 30-day survival.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Bajaj JS, Tandon P, OʼLeary JG, et al. The Impact of Albumin Use on Resolution of Hyponatremia in Hospitalized Patients With Cirrhosis. Am J Gastroenterol. 2018. PMID: 29880972. doi:10.1038/s41395-018-0119-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。